Generic Qbrelis Availability
Last updated on Apr 10, 2025.
Qbrelis is a brand name of lisinopril, approved by the FDA in the following formulation(s):
QBRELIS (lisinopril - solution;oral)
-
Manufacturer: AZURITY
Approval date: July 29, 2016
Strength(s): 1MG/ML [RLD]
Is there a generic version of Qbrelis available?
No. There is currently no therapeutically equivalent version of Qbrelis available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qbrelis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Lisinopril formulations
Patent 10,039,800
Issued: August 7, 2018
Inventor(s): Mosher Gerold L. & Miles David W.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC.Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 10,265,370
Issued: April 23, 2019
Inventor(s): Mosher Gerold L. & Miles David W.
Assignee(s): Silvergate Pharmaceuticals, Inc.Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 10,406,199
Issued: September 10, 2019
Inventor(s): Mosher Gerold L. & Miles David W.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC.Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 10,940,177
Issued: March 9, 2021
Inventor(s): Mosher; Gerold L. et al.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC. (Greenwood Village, CO)Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 11,179,434
Issued: November 23, 2021
Inventor(s): Mosher Gerold L. & Miles David W.
Assignee(s): Silvergate Pharmaceuticals Inc.Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 11,771,733
Issued: October 3, 2023
Inventor(s): Mosher; Gerold L. et al.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC. (Greenwood Village, CO)Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 12,128,083
Issued: October 29, 2024
Inventor(s): Mosher; Gerold L. et al.
Assignee(s): Azurity Pharmaceuticals, Inc. (Woburn, MA)Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 12,186,360
Issued: January 7, 2025
Inventor(s): Mosher; Gerold L. et al.
Assignee(s): AZURITY PHARMACEUTICALS, INC. (Woburn, MA)Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 9,463,183
Issued: October 11, 2016
Inventor(s): Mosher Gerold L. & Miles David W.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC.Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 9,616,096
Issued: April 11, 2017
Inventor(s): Mosher Gerold L. & Miles David W.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC.Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035✓
- November 6, 2035
-
Lisinopril formulations
Patent 9,814,751
Issued: November 14, 2017
Inventor(s): Mosher Gerold L. & Miles David W.
Assignee(s): SILVERGATE PHARMACEUTICALS, INC.Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
More about Qbrelis (lisinopril)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Angiotensin Converting Enzyme Inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.